Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease
© L'Episcopo et al; licensee BioMed Central Ltd. 2010
Received: 10 September 2010
Accepted: 23 November 2010
Published: 23 November 2010
Current evidence suggests a role of neuroinflammation in the pathogenesis of Parkinson's disease (PD) and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of basal ganglia injury. Reportedly, nonsteroidal anti-inflammatory drugs (NSAIDs) mitigate DAergic neurotoxicity in rodent models of PD. Consistent with these findings, epidemiological analysis indicated that certain NSAIDs may prevent or delay the progression of PD. However, a serious impediment of chronic NSAID therapy, particularly in the elderly, is gastric, renal and cardiac toxicity. Nitric oxide (NO)-donating NSAIDs, have a safer profile while maintaining anti-inflammatory activity of parent compounds. We have investigated the oral activity of the NO-donating derivative of flurbiprofen, [2-fluoro-α-methyl (1,1'-biphenyl)-4-acetic-4-(nitrooxy)butyl ester], HCT1026 (30 mg kg-1 daily in rodent chow) in mice exposed to the parkinsonian neurotoxin MPTP.
Ageing mice were fed with a control, flurbiprofen, or HCT1026 diet starting ten days before MPTP administration and continuing for all the experimental period. Striatal high affinity synaptosomial dopamine up-take, motor coordination assessed with the rotarod, tyrosine hydroxylase (TH)- and dopamine transporter (DAT) fiber staining, stereological cell counts, immunoblotting and gene expression analyses were used to assess MPTP-induced nigrostriatal DAergic toxicity and glial activation 1-40 days post-MPTP.
HCT1026 was well tolerated and did not cause any measurable toxic effect, whereas flurbiprofen fed mice showed severe gastrointestinal side-effects. HCT1026 efficiently counteracted motor impairment and reversed MPTP-induced decreased synaptosomal [3H]dopamine uptake, TH- and DAT-stained fibers in striatum and TH+ neuron loss in subtantia nigra pars compacta (SNpc), as opposed to age-matched mice fed with a control diet. These effects were associated to a significant decrease in reactive macrophage antigen-1 (Mac-1)-positive microglial cells within the striatum and ventral midbrain, decreased expression of iNOS, Mac-1 and NADPH oxidase (PHOX), and downregulation of 3-Nitrotyrosine, a peroxynitrite finger print, in SNpc DAergic neurons.
Oral treatment with HCT1026 has a safe profile and a significant efficacy in counteracting MPTP-induced dopaminergic (DAergic) neurotoxicity, motor impairment and microglia activation in ageing mice. HCT1026 provides a novel promising approach towards the development of effective pharmacological neuroprotective strategies against PD.
Selective degeneration of dopaminergic (DAergic) neurons in the subtantia nigra pars compacta (SN) is a pathological hallmark of both Parkinson's disease (PD) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of PD. The decline of dopamine in the striatum is associated clinically with progressive bradykinesia, tremor, rigidity and postural instability . Current DAergic treatments improve the motor symptoms and quality of life for patients during the early stages of PD but do not prevent the progression of the disease associated with disabling side-effects . With the exception of inherited cases linked to specific gene defects that account for <10% of cases, PD is a sporadic condition of unknown causes. Besides host genetics, environment, age, gender and inflammatory processes are factors affecting disease onset and/or progression [3–18].
Activation of microglia, a hallmark of neuroinflammation, has been demonstrated in the SN of PD patients , in human patients exposed to MPTP , and in experimental models of PD [21–35]. Accumulation of reactive oxygen species (ROS), inflammatory-associated factors including cycloxygenase-2 (COX-2) and inducible-nitric oxide synthase (iNOS)-derived NO, and pro-inflammatory cytokines (including TNF-α, IL-1β and IFN-γ) in the SN of PD patients further support that a state of chronic inflammation characterizes PD brain [5, 22–26]. In addition, elevated expression of macrophage-antigen complex 1 (Mac-1), a β2-integrin family member expressed exclusively in microglia, and NADPH oxidase (PHOX), one of the major sources for production of ROS or related reactive nitric species (RNS) in activated microglia, have been reported in PD animal models [8, 11, 13–16, 22–35]. In keeping with these findings, genetic or pharmacological inhibition of most inflammatory factors, including iNOS, PHOX, Mac-1 and COX-2-derived mediators, significantly attenuated DAergic degeneration in experimental models of PD [27–44]. Conversely, blocking the action of endogenous anti-inflammatory molecules, such as glucocorticoid hormones in transgenic mice expressing a glucocorticoid receptor (GR) antisense RNA, sharply increases microglial activation in response to MPTP, resulting in increased DAergic neuron vulnerability [8, 10, 11].
Consistent with the inflammation hypothesis, epidemiological analysis has indicated that nonsteroidal anti-inflammatory drugs (NSAIDs) may prevent or delay the progression of PD [6, 7, 45–52]. NSAIDs are among the most widely used therapeutic agents for the treatment of pain, fever and inflammation. Their effects are largely attributed to the inhibition of the enzymatic activity of COXs, of which there are two isoforms, COX-1 and COX-2. Both enzymes are responsible for arachidonic acid conversion in different prostaglandins (PGs) [53, 54]. While COX-1 is constitutively expressed in most tissues, COX-2 is induced during pathophyiological responses to inflammatory stimuli . Both mixed and selective COX-2 inhibitors have been reported to mitigate DAergic neurotoxicity in experimental models of PD; or to reduce LPS-induced neuronal damage [recently reviewed in [45, 46]]. Besides targeting COXs, NSAIDs can act in a COX-independent way, which includes activation of the nuclear factor peroxisome proliferator-activated receptor-γ (PPAR-γ), the protection against glutamate and 1-methyl-4-phenylpyrdinium ion (MPP+) toxicity, scavenging hydroxyl and NO radicals and dopamine-quinone formation [18, 45–48].
Nevertheless, the long-term therapy with non-selective NSAIDs is characterized by significant adverse effects on gastrointestinal tract and kidneys, whereas increased risk of cardiovascular events has been reported with COX-2-selective inhibitors , which may limit their clinical use in chronic conditions. The nitric oxide (NO)-NSAID HCT1026 [2-fluoro-α-methyl(1,1'-biphenyl)-4-acetic-4-(nitrooxy)butyl ester], NO-donating flurbiprofen, belongs to a novel class of anti-inflammatory agents obtained by derivatization of conventional NSAIDs with a NO-donating moiety which strongly reduce their untoward side effects without altering the anti-inflammatory effectiveness [57–66].
We herein report that HCT1026 has a safer profile and a greater efficacy than its parent compound in rescuing nigrostriatal DAergic neurons from MPTP neurotoxicity and that a shift in microglial pro-inflammatory phenotype is involved in this phenomenon. HCT1026 is safe at the gastrointestinal level, and it has been tested in humans; it is effective on oral administration, and it is thus suited for long-term treatment, thereby representing a promising approach towards the development of effective pharmacological neuroprotective strategies against PD.
Young adult (2-5 months of age) and ageing (9-11 month-old) male C57BL/6 (Charles River, Calco, Italy) housed (5 mice/cage) in a temperature (21-23°C), humidity (60%), and light (50/50 light:dark cycle, lights on at 06.00 a.m) controlled room, with controlled access to food and water, were allowed to acclimate one week before the start of the experimental protocol. Studies were conducted in strict accord with the Guide for the Care and Use of Laboratory Animals (NIH), and approved by the Review Boards of the OASI Institute (Troina, Italy). The authors further attest that all efforts were made to minimize the number of animal used and their suffering.
The drugs were compounded in the chow (Teklad 2018 diet, Harlan), the schedule of administration defined according to a pilot experiment conducted to monitor daily food intake, and the dose selected as that producing a full anti-inflammatory effect . The following doses were used: HCT1026 190 ppm in the diet or 30 mg kg-1 day-1 per animal; flurbiprofen 120 ppm or 20 mg kg-1 day-1 per animal Flurbiprofen dose was equimolar to HCT1026 (MW HCT1026:361.4; flubiprofen:244.3, ratio HCT1026/flurbiprofen = 1.48). Plain teklas 2018 chow was used as control diet. The treatment started 7-10 d days prior MPTP administration and thoroughout the entire experiment. Food consumption was monitored daily, diets were weighed and and food intake calculated daily, body weights recorded.
Experimental design, animal number and analyses performed per time-point (tp) within each experimental group.
Days after MPTP discontinuation
Sacrifice and tissue processing
Controls and MPTP-treated mice were killed at selected times ranging from 0-40 days post- MPTP treatment (dpt). To study early drug effects on microglia activation during the active degeneration phase, groups of mice were studied 1-7 dpt (Table 1). To monitor the severity of nigrostriatal damage and the survival/neurorescue of nigrostrial neurons, group of mice were studied 7, 21, 30 and 40 dpt. MPTP-induced motor deficit was assed with the Rotarod, at -7, + 1, + 3 and + 7 dpt. For neurochemical determinations, heads were cooled by rapid immersion in liquid nitrogen. Thereafter, striata of both sides and ventral mesencephalon, were rapidly removed and frozen at -80°C for subsequent determinations . For histopathological determinations, mice were deeply anesthetized and perfused transcardially, as reported in full details .
Determination of drug plasma level
Blood samples were taken at the indicated times and plasma samples were frozen and stored at -80° until the analysis was performed. Plasma 0.1 ml was mixed with 10 μl ketoprofen (internal standard, 1 mg ml-1 stock solution in methanol) and 400 μl of cold methanol/acetonitrile (1:1) mixture, vortexed and centrifuged at 13,000 × g for 10 min at 25°C. HPLC analysis was performed on fixed volume of organic extraction mixture. Chromatographic analysis was performed on an Agilent 1100 series system equipped with a Diode array detector operating at 246-nm single wavelenghth. Separations were achieved with a gradient elution on a Synergi MAX-RP 80A column (150 × 2 mm i.d.; 4 μm) equipped with MAX-RP precolumn (4 × 2 mm i.d.). The mobile phase was acetonitrile and phosphoric acid 0.1%. The flow rate was 1 ml min-1 and the column temperature was 25°C. Under these conditions, the retention time of HCT1026, flurbiprofen and internal standard were 5.7, 1.3, 0,8 min, respectively. Only flurbiprofen was detectable in plasma of HCT1026 treated mice. HCT1026 and its des-nitro metabolite (i.e. HCT1027) were undetectable in all plasma samples, as previously reported .
Motor behavior analysis with the rotarod
An accelerating rotarod (five-lane accelerating rotarod; Ugo Basile, Comerio, Italy) was used to measure motor balance and coordination in mice. Mice have to keep their balance on a horizontal rotating rod (diameter, 3 cm) and rotation speed was increased every 30 sec by 4 rpm. Five mice were tested at the same time, separated by large disks. A trial starts when the mouse is placed on rotating rod, and it stops when the mouse falls down or when 5 min are completed. Falling down activates a switch that automatically stops a timer. The testing day, each mouse is submitted to 5 trials with an intertrial interval of 30 min. Mice housed five per cage were acclimated to a 12 h shift in light/dark cycle so that the exercise occurred during the animals normal wake period. Saline- and MPTP-treated mice fed with a control or HCT1026 diet (10/experimental group) were assessed for their Rotarod performance on day -7, +1, + 3 and +7 dpt.
High-affinity [3H]dopamine uptake assay
Left and right striata were homogenized in ice-cold pre-lysis buffer (10 mM Tris, pH 7.5, and 0.32 M sucrose) using a Teflon pestle-glass mortar and homogenized tissue centrifuged for 10 min at 1000 × g at 4°C to remove nuclei. The supernatant containing the synaptosomes was collected and aliquots removed for the determination of protein content  and dopamine uptake (total high affinity and mazindol non-inhibitable). Fifty microliters of supernatant were diluted in Krebs-Ringer phopshate buffer (16 mM NaH2PO4,16 mM Na2HPO4, 119 mM NaCl, 4.7 mM KCl, 1.8 mM CaCl2, 1.2 mM MgSO4, 1.3 mM EDTA, and 5.6 mM glucose; pH 7.4), and incubated at 37°C in the presence or absence of mazindol (10 μM), a high affinity dopamine up-take inhibitor . [3H]Dopamine (25 nM, specific activity, 20-40 Ci/mmol; Amersham, Arlington Heights, IL) was added in Krebs-Ringer buffer and incubation carried on for 6 min at 37°C. Synaptosomes were collected on presoaked nitrocellulose filters by filtration and non-specific radioactivity was washed with Krebs-Ringer phosphate buffer followed by filtration. The filters were then transferred into scintillation vials and measured by liquid scintillation (Cytoshint; ICN, Costa Mesa, CA) counter (Packard). Specific high-affinity neuronal dopamine uptake is expressed as fentomoles of dopamine uptake per microgram of protein minus the fentomoles of mazindol uptake. Values are represented as % changes in dopamine uptake vs. control.
Measurement of MPP+ levels in the striatum
Mice fed with the different diets were killed 90 min after MPTP injection. Both left and right striata were dissected on ice, placed into a vial containing 250 ul of 0.4 N perchloric acid and sonicated. After centrifugation, MPP+ determinations were carried out by HPLC using 5SCX column (Phenomenex). The mobile phase was composed of H2S04 0.1 M, triethylamine 0.075 M, and acetonitrile 10% at pH 2.3; the flow was 1.5 ml mn-1 .
On the day of sacrifice, mice were anesthetized by intraperitoneal injection of Nembutal (50 mg/kg). Mice were rapidly perfused transcardially with 0.9% saline, followed by 4% paraformaldehyde in phosphate buffer (pH 7.2 at 4°C). Brains were carefully removed and post-fixed for 2-4 hrs, in 4% paraformaldehyde in phosphate buffer saline, pH 7.2 (PBS) and later placed in 15% sucrose in PBS overnight at 4°C. Tissues were frozen at -80° C. Serial cryostat sections (10 μm, from the olfactory bulb to the end of the medulla), were collected, mounted on poly-L-lysine-coated slides and processed for immunohistochemistry. Identification of the level was made by comparison with the sections of the mouse brain . All immunostaining procedures were carried out on sections incubated in blocking buffer (0.3 - 0.5% Triton X-100, 5% BSA and 5% normal serum in PBS) for 30 min at room temp followed by an overnight incubation with the following primary antibodies in blocking buffer at 4°C: (i) tyrosine hydroxilase (TH) (goat anti-TH, Santa Cruz Biotechnology, Inc. USA 1:1000; rabbit anti-TH Pelfreez, Roger, AR, 1: 2000); (ii) rat anti dopamine transporter DAT, Millipore Corp. USA, 1:1000), as markers of dopaminergic neurons; (iii) membranolytic attack complex of complement (rat anti Mac-1/CD11b, Pharmingen International, Becton Dickinson, USA or anti Mac-1, Serotec, Oxford, UK, 1: 1000), as microglial marker; (iv) inducible nitric oxide synthase (rabbit anti-iNOS, Santa Cruz Biotechnology, Inc, 1: 200), 3-nitrotyrosine (rabbit anti-3-NT, Upstate, Lake Placid, NY, US, 1: 200), as NO/peroxynitrite finger-print. The sections were counterstained with nuclear counterstain (Dapi or PI, by Vector Laboratories Inc. Burlingame, CA, USA).
All antibodies, whether used for single or dual labeling procedures, were visualized by immunofluorescence, except for TH-Ab that was also visualized using immunoperoxidase. Adjacent tissue was also stained with cresyl violet to validate TH neuron survival [8, 73, 74]. Sections were incubated with the indicated dilutions of the antibodies, either alone or in combination as described. After 3 (× 5 min) washes in PBS, primary antibodies were revealed with specific FITC and CY3 conjugated secondary antibodies 1:100-1:200 dilution. (60 min at room temp). After 3 (× 5 min) washes in PBS, sections were mounted with Gel mounting solution (Biomeda corp. Foster City, CA, USA). In all of these protocols, blanks were processed as for experimental samples except that the primary antibodies were replaced with PBS.
Loss of TH-positive neurons and striatal DAergic innervation
Loss of TH-positive (TH+) SNpc neurons was determined by serial section analysis of the total number of TH+ cells counted throught the entire rostro-caudal (RC) axis of the murine SNpc (Bregma coordinates: -2.92, -3.08, -3.16, -3.20, -3.40 and -3.52) according to Franklin and Paxinos  at 7, 21, 30 and 40 days post-MPTP (dpt) or saline injection . Cell counting was done in both side of the brain for each animal, and then right and left values were added to generate a total DA SNpc neuron count, in a total of five animals per experimental group. TH-labeled neurons were scored as positive only if their cell-body image included well defined nuclear counterstaining. Estimates of total TH+-stained and cresyl-violet-stained neurons in the SNpc were calculated using the Abercrombie's correction . The total number of TH+ cell bodies was estimated and examined by two independent researchers, in a blind fashion. Loss of striatal DAergic innervation was assessed by quantification of TH- and DAT-immunofluorescent (IF) signal intensity in 10 μm-thick coronal sections located at 0.5, 0.8 and 1.1 mm from bregma, and analyses carried out by confocal laser miscroscopy as described .
Confocal laser microscopy and image analysis
Sections labeled by immunofluorescence were visualized and analyzed with a confocal laser scanning microscope LEICA TCS NT (Version 1.0, Leica Lasertechnik GmBH, Heidelberg, Germany), equipped with an argon/krypton laser using 10 ×, 20 ×, and 40 × and 100 × oil-immersion objectives. Pinhole was set at 1-1.3 for optical sections of 0.48-0.5 μm. For TH+ and DAT+ fibers in striatum, fluorescence intensity per unit of surface area was determined in 10 randomly selected fields (250.000 μm2) using computer-assisted image analysis software (LEICA). Single lower power scans were followed by 16 to 30 serial optical sectionings. Laser attenuation, pinhole diameter, photomultiplier sensitivity, and off-set were kept constants. The average fluorescence intensity (pixel, mean ± SEM per unit surface area) was measured throught the stack. Within the same stacks, the background pixel intensity in areas devoid of fibers/cells was determined and substracted. For assessment of reactive microglial cell number, ameboid-shaped Mac-1+ cells  were counted in striatal and SNpc coronal sections, cell counts averaged for each animal and the mean number of cells per mm2 per animal was estimated. A comparable countable area ranging from 1.90 mm2 to 2.00 mm3 was analyzed in the different MPTP groups. Double-labelled cells with iNOS and Mac-1, were counted and expressed as above. Dual stained TH+ 3-NT+ cells were counted and values expressed as a percent double-stained TH+ NT+ /TH+ neurons. Each label was analyzed on a total of 12 sections per mice and in at least 4 mice per group. Analyses were performed by two independent researchers blind to the experiment.
To analyze transcript levels, total RNA was isolated from striatum and ventral mid brain using the RNeasy isolation Midi kit (Qiagen, #75144). Tissue samples were homogenized in 1 ml of QIAzol Lysis Reagent (Qiagen, #79306) using a rotor-stator homogenizer. Total RNA was isolated from homogenized tissue samples using RNeasy Lipid Tissue Kit (Qiagen, #74804) including DNase digestion. At the end, RNA samples were redissolved in 30 μl of RNase-free water and their concentrations were determinated spectrophotometrically by A260 (Nanodrop-ND 1000). The cDNA was synthesized from 2 μg of total RNA using the Retroscript Kit (Ambion, #AM2224) following the manufacturer's directions. 250 ng of cDNA were used for PCR (96°C for 1 min for 2 cycles; 96°C for 1 min, 58°C for 4 min; 94°C for 1 min, 58°C for 2,5 min for 35 cycles, with a final extension at 70°C for 10 min) by using Super Taq DNA polymerase (Ambion, #AM1710) with specific primer pairs for TH (F: cgtggaatacacaaaggagg; R:ggtaggtttgatcttggtag; amplicon: 620 bp); DAT (F:cagagaggtggagctcatc; R:ggcagatcttccagacacc; amplicon: 328 bp), iNOS (F: tgctcccttccgaagtttctggcagcagcg; R: tcagagcctcgtggctttgggctcctc, amplicon: 500 bp) and Classic S18 Standard (amplicon: 495 bp; #Ambion AM1720), to normalize the expression. Samples from PCR reactions were separated electrophoretically on 2% agarose gel containing 0,2 μg ml-1 of ethidium bromide. Fluorescent bands of amplified gene products were captured by using Gel Logic 200 Imaging System (Kodak), values normalized against S18, and ratios expressed as percent of control (saline-injected), within each experimental group.
Western blot analysis
Protein extracts were prepared for striatum and ventral midbrain (which included the SNpc) (left and right sides) at the indicated time-intervals after saline or MPTP injections (n = 3 per group). The tissue samples were homogenized in lysis buffer (0.33 M sucrose, 8 mM Hepes, pH 7.4 and protease inhibitors) and quantified using the BCA protein determination method (Bio-Rad, Hercules, CA). Protein samples were diluted to equivalent volumes containing 20 μg of protein and boiled in an equal volume of Laemli SDS boiling buffer (Sigma) for 10 min. Samples were loaded into a 9-12% SDS-polyacrilamide gel and separated by electrophoresis for 3 h at 100 V. Proteins were transferred to polyvinylidene difluoride membrane (Amersham Biosciences, Piscataway, NJ) for 1.5 h at 300 mA. After blocking of nonspecific binding with 5% nonfat dry milk in TBST, the membranes were then probed with the following primary antibodies: rabbit anti-TH (Chemicon); rat anti-DAT (Millipore), rabbit anti-Mac1 (AbCam), mouse anti-gp91phox (BD Transduction Laboratories), β-actin (Cell Signaling). After incubation at room temperature for 1 hr, membranes were washed and treated with appropriate secondary antibodies conjugated with horseradish peroxidase (HRP) and blot were exposed onto radiographic film (Hyperfilm; Amersham Bioscience). Membranes were reprobed for β-actin immunolabeling as an internal control. The bands from the Western blots were densitometrically quantified on X-ray films (ImageQuantity One). The data from experimental band were normalized to β-actin, before statistical analysis of variance and values expressed as % of saline-injected controls.
Data were analyzed by means of two-way analysis of variance (ANOVA), with group and time as independent variables and given as mean±SEM. Striatal neurochemical data (nmol or pmol mg protein-1) are expressed as % of controls. Comparisons a posteriori between different experiments were made by Student-Newman-Keuls t-test.
HCT1026 preventive administration counteracts MPTP-induced down-regulation of high affinity synaptosomial DA uptake in the striatum
The preventive oral administration with HCT1026 was well tolerated and did not cause any measurable toxic effect throught the treatment, whereas flurbiprofen-fed mice showed severe gastrointestinal side-effects (bleeding). Due to flurbiprofen toxicity, only HCT1026 was studied in the long-term experimental protocol.
To more closely mimick PD condition, we next assessed the longterm efficacy and safety of HCT1026 in ageing (9-11 month-old) mice. Reportedly, the process of ageing increases DAergic vulnerability to MPTP and limits the repair capacity of the nigrostriatal DAergic system [77, 78]. We thus selected the subchronic MPTP regimen, at a dose of 15 mg/kg [28, 32, 42]. Consistent with previous findings [77, 78], ageing mice fed with a control diet did not recovered from MPTP insult, as revealed by an almost 70-75% decrease of DA uptake levels measured up to 40 dpt, whereas in mice fed with HCT1026, a significant degree of protection was measured, as reflected by the significant amelioration of striatal DA uptake levels at all time-points studied (Figure 1C). These data indicate that the neuroprotective activity of HCT1026 was maintained up to 40 dpt. In addition, the longterm administration of HCT1026 does not cause any measurable toxic effects.
HCT1026 inhibits MPTP-induced motor impairment
To verify the ability of HCT1026 to affect MPTP-induced impairment of motor coordination [42, 79, 80], we assessed the ability to maintain the balance on a rotating cylinder and to adapt to the rate of locomotor activity, by using the Rotarod test, as described (Figure 1D). Saline- and MPTP-treated mice fed with a control or HCT1026 diet (n = 10/experimental group) were assessed for their Rotarod performance one week before saline or MPTP treatment (day -7) and + 1, + 3 and + 7 d post-MPTP. Because of the high degree of challenge of this task, mice of saline injected groups (-MPTP) fed with either a control or HCT1026 diet, performed better on the second trial (+ 1 d) and subsequent days, compared with d -7. By contrast, MPTP-treated mice fed with a control diet exhibited a significant decrease in the mean latency to fall at all time-points tested, compared to saline-injected mice (p < 0.05), defining a motor deficit in MPTP-treated animals (Figure 1D). In MPTP mice fed with HCT1026, the mean latency to fall was significantly (p < 0.05) increased compared to MPTP mice fed with a control diet at all time tested. By 7 dpt, HCT1026-fed mice performed as good as the control mice, indicating a significant reduction of the motor impairment by the preventive treatment with HCT1026.
HCT1026 inhibits MPTP-induced loss of striatal TH and DAT at mRNA and protein levels
MPTP metabolism is not affected by HCT1026 preventive treatment
One of the first limiting factors in MPTP toxicity is the conversion of MPTP into MPP+ by means of the monoamine oxidase B (MAO-B) enzymatic activity. MPP+ is known to gain access into neurons via DAT, and through this mechanism it is accumulated into DAergic cells causing selective toxicity . The striatal levels of MPP+ were then measured 90 min after MPTP injection in mice fed with the different diets and exposed to MPTP. There was no significant difference in striatal MPP+ levels measured 90 min after MPTP injection in mice fed with either the control (110 ± 7 ng mg-1 protein) or HCT1026 (124 ± 12 ng mg-1 protein) diets, thereby indicating that the greater protection afforded by HCT1026 might not be attributed to poor MPP+ metabolism.
HCT1026 preventive administration decreases MPTP-induced loss of TH+ cell bodies in SNpc
In order to verify the ability of the continous oral treatment with HCT1026 to maintain its neuroprotective effects, saline and MPTP (15 mg kg-1 day-1 per 5 consecutive days), mice fed with the control or HCT1026 diet were sacrificed at 21, 30 and 40 dpt. As observed, at either 7 d (Figure 5A, B, C and 5M), 21, 30 (Figure 5M), or 40 dpt (Figure 5G, H, I and 5M) MPTP mice fed with the control diet did not recover as reflected by the significant, long-lasting loss of TH+ Nissl+ neurons. In sharp contrast, HCT1026 exerted a significant neuroprotective effect that was maintained up to 40 dpt (see Figure 5D, E, F, and 5J, K, L, M), suggesting increased survival/rescue of SNpc neurons in HCT1026-fed mice.
HCT1026 inhibits MPTP-induced microglial activation
Glial inflammatory mechanisms are thought to contribute to MPTP-induced nigrostriatal DAergic degeneration (see Refs in Background). Indeed, when microglia adopts a pro-inflammatory phenotype, the production and release of a plethora of toxic mediators, including pro-inflammatory cytokines and iNOS-derived NO, can enhance neuronal damage in the SNpc and accelerate the appearance of behavioral symptoms [32, 81–83]. The ability of HCT1026 to modulate MPTP-induced microglial activation was next assessed during the early phase of active degeneration  using immunohistochemistry, WB and RT-PCR analysis.
Microglial cell number/morphology in striatum and SNpc
Mac-1 and PHOX expression in the ventral midbrain (VM)
Expression of pro-inflammatory mediators: iNOS and 3-NT
The ability of a preventive treatment with HCT1026 to inhibit MPTP-induced up-regulation of iNOS was next evaluated by semi-quantitative RT-PCR analysis 1 d after MPTP challenge. Within the ventral midbrain of saline-treated mice fed with a control or HCT1026 diet, no significant difference was observed in iNOS mRNA levels, whereas MPTP significantly up-regulated iNOS transcription (Figure 7C). On the other hand, the MPTP mice fed with HCT1026 exhibited significantly less iNOS mRNA expression compared to controls (Figure 7C).
When glial superoxide generated by PHOX activation and iNOS/NO are concomitantly active, peroxynitrite (ONOO-), and consequently protein tyrosine nitration and hydroxyl radicals over-production occurs . Hence, the generation of high NO concentration followed by the production of peroxynitrite may be involved in DAergic neuronal cell death. We thus used immunohistochemistry to localize iNOS and 3-nitrotyrosine (3-NT) as fingerprint of iNOS-derived NO and peroxynitrite generation. Dual immunostaining with iNOS and Mac-1 within the SNpc of MPTP mice fed with a control diet, indicated that a significant proportion of reactive Mac-1 cells expressed iNOS, 1-7 d post-MPTP (Figure 7D, E). Dual staining with 3-NT- and TH indicated a sharp increase in the percentage of TH+ cells colocalizing with 3-NT at both 1 and 3 d post-MPTP (Figure 7G, H), while a certain decrease was observed 7 dpt. Conversely, in MPTP mice fed with HCT1026, both iNOS- (Figure 7D, F) and 3-NT-(Figure 7G, I) were significantly downregulated 1-7 dpt within the SNpc.
These results indicated an efficient reduction of MPTP-induced microglial activation, pro-inflammatory marker expression, i.e. Mac-1, PHOX, iNOS and 3-NT formation within the SNpc of mice fed with HCT1026, which might account for the observed nigrostriatal protection.
Grafting a NO-donating moiety into the structure of flurbiprofen, one of the most potent non-selective anti-inflammatory agents, yielded a drug devoided of side toxicity and endowed with a remarkable neuroprotective activity against MPTP-induced DAergic neurotoxicity, motor impairment and microglia activation in ageing mice. HCT1026 was effective in both the acute and subchronic models of MPTP, and its neuroprotective activity lasted up to 40 d, as opposed to age-matched controls indicating the longterm safety and efficacy of the HCT1026, as opposed to flurbiprofen. The different outcome of mice treated with HCT1026 was not due to differences in daily food consumption, or to poor MPP+ metabolism. HCT1026-induced neuroprotection was associated with a marked down-regulation of activated microglial cell number and a signiof ficant decrease of MPTP-induced pro-inflammatory mediators, including iNOS, Mac-1 and PHOX expression, as well reduced 3-NT formationin SNpc DAergic neurons, suggesting that a switch in microglia pro-inflammatory phenotype might contribute to nigrostriatal neuroprotection.
The experimental study was designed to compare the oral activity of HCT1026 with that of flurbiprofen. However, due to the significant gastric toxicity of flurbiprofen observed in the short-term study, only HCT1026-medicated diet was further studied. In long-term experimental protocols, HCT1026 proved to have a safe profile and a significant efficacy in counteracting MPTP-induced striatal DAergic toxicity.
Nitric oxide (•NO) is a biological molecule known to play a major role in a wide variety of physiological and pathological conditions . Some of its functions include vasodilation of blood vessels, GI mucosal healing and defense. Therefore NSAIDs containing NO-donor groups have been developed to obtain effective treatment of inflammation with reduced GI side effects [57–61]. Indeed, grafting an organic nitrate moiety onto the NSAID scaffold has been shown to result in the release of NO through slow kinetics (in comparison with others NO donors, i.e. sodium nitroprusside, S-nitroso-N-acetyl-D,L, penicillamine), possibly mimicking the physiological levels of NO produced by constitutive NO synthases. Thanks to NO release, and the combination of a balanced inhibition of the two main COX isoforms, NO-NSAIDs are endowed with little gastrointestinal and renal toxicity compared to their parents compounds [56–61, 65, 85]. It is believed that the NO, which is released by the metabolism of nitrate as the compounds are broken down, may counteract the consequences of the NSAID-induced decrease in gastric mucosal PGs . It seems important to mention that a clear identification of the metabolic steps by which NO-NSAIDs produce NO has not been established. Experimental findings obtained, in vivo, show that HCT1026 is metabolized into flurbiprofen and NO species, i.e. nitrates and nitrites, [60, 61, 70], which are detected in plasma and in brain at 2-4 h  and 3 h , respectively from drug administration. In vitro, HCT1026 is converted into flurbiprofen with different kinetics depending on the cell assay. In rat plasma, 30 min of incubation is required to fully convert HCT1026 to flurbiprofen [see ]. By contrast, approximately 35% of HCT1026 is converted into flurbiprofen within 1 h of incubation in human blood, and 24 h of incubation was necessary to reach the almost complete dissociation of HCT1026 [62, 63]. Given the rapid action of HCT1026 demonstrated in vitro, Bernardo et al.  suggested the possibility that HCT1026 might reach the brain parenchyma and act on brain cells before being cleaved to the nitrate moiety and flurbiprofen . Alternatively, the metabolites flurbiprofen and NO might act concomitantly by activating parallel pathways that ultimately determine the unique effects of HCT1026 . Other studies have suggested a potential action of the HCT-1026 metabolite, 4-hydroxybutyl nitrate, since animal studies have shown that the level of inorganic nitrite in the brain increases after oral administration of HCT-1026 . Plasma nitrite itself has been shown to provide a source of NO under certain conditions [see ].
Neurochemical, morphological and behavioral changes clearly indicate that with the ageing process, increased vulnerability of the nigrostriatal DAergic system and limited recovery from MPTP injury are observed [4, 5, 17, 18, 77, 78]. Indeed, the nigrostriatal DAergic neurons exhibit compensatory mechanisms in response to MPTP injury, but the degree of plasticity becomes reduced with age [18, 77, 78]. Accordingly, a diminished compensatory capacity of nigrostriatal DAergic neurons "as a prelude" to PD is recognized to accompain the process of aging [see [88, 89]]. Among the mechanisms at play, increased neuronal vulnerability to degenerative conditions, dysfunction of glia-neuron crosstalk, reduced repair capacity of injured DAergic neurons and/or limited neurogenesis may contribute to the poor recovery observed with age [see  for review]. Given the role of the ageing process as a critical risk factor for developing PD, we addressed the efficacy of HCT1026 preventive administration schedule in 9 to 11 month-old mice and found that longterm administration of HCT1026 resulted in a significant DAergic neuroprotection following MPTP insult, at both and SNpc levels. These effects lasted up to 40 dpt, supporting HCT1026 as promising approach towards the development of effective pharmacological neuroprotective strategies against PD.
Variable neuroprotective effects have been, so far, reported for both steroidal and non-sterodal, mixed and COX-2-selective inhibitors in different MPTP-mouse models of PD [37–48]. The mixed COX-1/COX-2 inhibitor indomethacine  and a COX-2 selective NSAID, rofecoxib  treatment rescued DAergic neurons from MPTP injury. Indomethacine, however, appeared toxic at high doses, and rofecoxib, failed to keep its protective properties when used in the prolonged treatment . Studies on mice deficient with COX-2 showed that COX-2 plays a critical role in animal models of DAergic degeneration [38, 32, 43]. In particular, the role of increased levels of COX-2 in generating a toxic dopamine-quinone species which was responsible for DAergic neuronal degeneration, was demonstrated, whereas the selective COX-2 inhibitor, rofecoxib, exhibited a neuroprotective effect (38). In the study of Sanchez-Pernaute , the COX-2 antagonist, celecoxib, was capable to prevent or slow down DAergic degeneration induced by intrastriatal administration of 6-OHDA. Accordingly, Vijitruth et al.  showed that pharmacological or genetic inhibition of COX-2 was capable to reduce motor impairment and to protect DAergic neuronal cell bodies in the SNpc as well as the striatal TH-stained fibres against MPTP-induced neurotoxicity .
On the other hand, Ibuprofen, a non selective blocker, was shown to diminish the decline of dopamine content in striatum in the MPTP mouse model of PD, in a dose-dependent manner, and was not toxic to the DAergic system . In accord with these experimental results, ibuprofen, but not other non-selective NSAIDs, was shown to diminish the risk/incidence of PD in men [5, 6]. The present results showing the longterm DAergic neuroprotection in ageing mice and the safety profile of HCT1026 are of special interest, given that non-selective NSAIDs long-term therapies are hampered by their significant gastrointestinal, renal and cardiovascular side-effects [56, 85].
HCT1026-induced neuroprotection observed in the present study was accompanied by a sharp downregulation of all studied markers of microglial activation including ameboid-like microglial cell number, pro-inflammatory mediators as well as two key harmfull elements, MAC-1 and PHOX, likely suggesting that a shift from microglial pro-inflammatory ("harmfull") phenotype might be a major contributing factor.
Indeed, under inflammatory conditions, PHOX is the major source of peroxides in the brain. Activation of microglial PHOX is synergistic with glial iNOS expression in inducing DAergic neuron death [27–36]. Accordingly, PHOX/Mac-1-deficiency mitigates MPTP-induced DAergic neurotoxicity both in vivo and in vitro [30–33]. Inflammatory stimuli together with ROS and RNS activate nuclear factor-kB (NF-kB) in microglial cells, oligodendrocytes and neurons to promote the transcription of inflammatory cytokines, COX-2, iNOS, and apoptosis-promoting factor including p53/Bax [see [45, 46]]. Various studies (reported in Backgroud section) have clearly underlined a "dual key mechanism" whereby simultaneous activation glial iNOS and PHOX synergistically act in killing DAergic neurons . This mechanism may mediate inflammatory degeneration in response to cytokines, bacteria, ATP, arachidonate, whereas neuroprotection was observed by NO and peroxynitrite scavengers . Indeed, nitrative stress is among the factors potentially underlying DAergic neurodegeneration [8, 27, 28, 33–36]. Interestingly, the number of DAergic neurons containing 3-NT increased significantly in rhesus monkey midbrain DAergic neurons with age, suggesting a role for aging-related increase of nitrative damage in the selective vulnerability of SN neurons to degeneration in PD . Here, ageing mice fed with a control diet exhibited a dramatic increase of 3-NT colocalization with TH+ neurons by 3 d after MPTP, corresponding to the active DAergic degeneration phase [27, 28, 32, 33, 36], while by 7 d a certain decrease in 3-NT accumulation within TH+ neurons was observed, possibly indicating the end of the degeneration phase. In HCT1026-fed mice, the generation of PHOX and iNOS-derived cytotoxic mediators, including 3-NT accumulation within DAergic neurons, were markedly abated, supporting that a significant proportion of SNpc neurons survived MPTP insult.
Although NSAIDs pharmacological actions are related to their ability to inhibit PG biosynthesis, some of their beneficial therapeutical effects are thought to be mediated by a panel of COX-independent mechanisms. NSAIDs are able to inactivate the transcription NF-kB and activator protein-1 (AP-1), critically involved in the induction of multiple inflammatory gene products involved in the inflammatory response (i.e. iNOS, TNF-α). In addition, NSAIDs in neuronal cells might directly and dose-dependently scavenge ROS and RNS, thereby blocking their detrimental effects [45, 46]. On the other hand, high concentrations of NSAIDs such as ibuprofen and indomethacin, activate PPARγ. PPARγ is a ligand activated inhibitory transcription factor that antagonizes the activity of NFkB, AP1, signal transducer and activator of transcription-1 (STAT-1) and nuclear factor of activated T cells (NFAT). PPARγ activation is then associated with a reduction in the expression of several inflammatory genes and the production of inflammatory cytokines and iNOS [45, 46]. In particular, in vitro studies have reported that selective PPARγ agonists such as pioglitazone, ibuprofen, or indomethacin, can activate PPARγ in microglia, decreasing the number of activated glial cells [see [45, 46]].
The mechanisms that differentiate HCT-1026 from flurbiprofen remains a matter of debate. In vitro studies demonstrated that a low concentration of (1 μM) of HCT1026, but not flurbiprofen, activated PPARγ in primary cultures of rat microglia, with kinetics similar to those of the synthetic agonist, ciglitazone , supporting additional anti-inflammatory action through PPARγ . In addition PPARγ agonists were reported to mitigate MPTP-induced DAergic neurotoxicity in different PD models [see [13–15, 45, 46]]. In the recent studies of Abdul-Hay et al. , flurbiprofen was 10-fold less potent than HCT-1026 in inhibiting iNOS induction in RAW 264.7 cell cultures. In LPS/IFNγ-induced primary astroglial cultures, HCT-1026 showed anti-inflammatory potency towards inhibition of cytokine and iNOS elevation, providing similar observations to those in microglial cultures . That the anti-inflammatory activity of HCT-1026 could translate into neuroprotection was further demonstrated in a co-culture experiment with LPS-stimulated RAW cells and a neuroblastoma cell culture, where HCT-1026 was highly efficacious neuroprotectant .
Grafting a NO-donating moiety to flurbiprofen was reported to confer additional anti-inflammatory properties [51, 52, 60–66, 87, 92, 93]. It has been suggested that this effect may depend on the negative feedback regulation exerted by low physiologic concentration of NO (nanomolar range) on different inflammatory mediators such as iNOS and COX-2, as well as on their associated functions [94–97]. Indeed, there is evidence that at low concentrations, NO has anti-inflammatory properties as it inhibits the expression of pro-inflammatory proteins (i.e. COX-2 and iNOS), and it counteracts the release of pro-inflammatory cytokines, such as TNF-α, in activated macrophages [94–97].
It should be recalled, that NO signaling plays an important role in the functioning of the CNS, and activation of soluble guanylate cuclase (sGC) represent one important effect of NO. Of note, physiological release of low concentrations of NO by constitutive neuronal NOS is recognized to modulate extracellular levels of dopamine in the striatum and to critically participate in striatal DAergic homeostasis . The NO/sGC/cGMP signal transduction system is also considered to be important for modulating synaptic transmission and plasticity in brain regions such as the hippocampus, cerebral cortex, and cerebellum, and further studies are required to unravel potential involvement of these pathways in DAergic neuroprotection afforded by HCT1026. Besides the NO-mediated effects, most recently proposed are NO-independent and NSAID-independent actions on NFκB and MAPK/ERK signaling pathways [see ]. In their study, Idris and co  reported the ability of HCT1026 to inhibit receptor activator of NFkB (RANKL), as well as RANKL-induced activation of NFkB and ERK pathway in LPS-stimulated macrophage cultures. In addition, HCT1026 also inhibited TNF-α, IL-1 and LPS-induced signaling. Interestingly enough, the pathways inhibited by HCT1026 all share a similar kinase complex upstream of the NFkB and ERK pathways and this is the most likely target for the action of HCT1026 .
It seems important to underline that inflammatory pathways may become hyperactivated with age and/or become more sensitive to immune/neurotoxic challenge, thereby promoting degeneration [99–102]. Given that with age, dysfunctional microglia and altered glia-neuron crosstalk may contribute to the progression of neuronal degeneration , HCT1026 preventive and long-term treatment might thus reduce age-dependent and MPTP-induced increase in oxidative and inflammatory attacks to nigrostriatal DAergic neurons. Of special interest, in view of the role of both systemic and central inflammation in modulating the severity of neuronal insult, including DAergic injury [see [13–15, 18, 24, 81–83]], a potential effect of HCT1026 in influencing systemic inflammation cannot be excluded. In addition, the mitigation of the nitrosative/oxidative status of the nigral microenvironment as revealed by downregulation of Mac-1, PHOX and 3-NT in the VM, likely have beneficial consequences for glial expression of critical neuroprotective/neurotrophic factors , thereby supporting TH+ neuron survival/neurorescue, possibly through an amelioration/mitigation of SNpc nicroenvironment.
After brain injury, the inflammatory environment is recognized to have both detrimental and beneficial effects on neuronal outcome, depending on mouse strain, age and sex of the host, the severity of the lesion, the degree and timing glial activation, the hormonal background, the specific cellular context and intrinsic region-specific neuronal characteristics [see [8–18, 21–26, 40, 77, 78, 100, 103, 104]]. In degenerative conditions, glia serve neuroprotective functions including the removal of dead cells by phagocytic activity and the production of neurotrophic factors. By contrast, overactivation of microglia or dysfunctional microglial cells as a consequence of ageing and age-related events within the SN microenviroment, [18, 25, 100–102] likely increase DAergic neuron vulnerability and/or may limit DAergic self-repair abilities. In vivo experiments have recently shown that intranigral administration of prostaglandin J2 (PJ2) induces microglia activation, selective degeneration of DAergic neurons in the SNpc, formation of ubiquitin- and α-synuclein-immunoreactive aggregates in the spared DAergic neurons, and locomotor deficit . These and other findings have underlined the role of a transient initiation factor, triggering an active self-perpetuating cycle of chronic neuroinflammation, contributing to DAergic neuronal dysfunction [13, 83]. By reducing exacerbation of inflammation, HCT1026 may then improve mitochondrial performance, increase glial-mediated neurotrophic support, thus creating a more favorable milieu for nigrostriatal DAergic neuron survival/rescue.
The present results are in line with data obtained in different animal models of brain inflammation, where HCT1026 significantly reduced neuronal loss and decreased the number of reactive microglial cells to a greater extent than the parent compound, flurbiprofen [66, 86, 87, 92, 93]. In experimental allergic encephalomyelitis (EAE), oral treatment with HCT1026 which delayed disease onset and decreased the severity of clinical signs in mice immunized with myelin oligodendrocyte peptide (MOG35-55) . In addition, HCT1026 fed mice exhibited significantly reduced mRNA levels of pro-inflammatory cytokines, caspase-1, and iNOS in blood cells, with reduced number of CNS-infiltrating T cells . Recently, HCT1026 was reported to mitigate amyloid-β-induced toxicity, in cell culture, in vitro, while enhancing cognition in response to cholinergic blockade, in vivo . Other studies reported the ability of HCT1026 to reduce microglia activation and to prevent muscular dystrophy pathology in two murine models .
We herein report that oral preventive administration of the NO-donating derivative of flurbiprofen, HCT1026, has a safe profile and a significant efficacy in counteracting MPTP-induced DAergic neurotoxicity, motor impairment and microglia activation in ageing mice. In particular, nigrostrial DAergic neuroprotection afforded by HCT1026 lasted for 40 d after MPTP administration. Hence, DAergic neurons exhibited an increased ability to resist to the cytotoxic environment caused by MPTP injury, leading to a significant neurorescue observed within the striatum and SNpc, at a morphological, neurochemical, and molecular levels. These effects of HCT1026 were associated with reduced microglial proinflammatory phenotype and reduced formation of the peroxynitrite footprint, 3-NT, within TH+ cell bodies. While further studies are required to clarify the mechanism(s) of HCT1026 neuroprotective effects, the combination of a balanced inhibition of the two main COX isoforms with NO release provides a promising approach towards the development of novel and effective therapeutic strategies against PD.
List of abbreviations
Experimental Allergic Encephalomyelitis
Inducible-nitric oxide synthase
Monoamine oxidase B
Myelin oligodendrocyte peptide
Nonsteroidal anti-inflammatory drugs
Peroxisome proliferator-activated receptor-γ
Reactive nitrogen species
Reactive oxygen species
Subtantia nigra pars compacta
Acknowledgements and funding
*The authors wish to thank the Italian Ministry of Health (Con. n° 82; Ps-CARDIO ex 56 to B.M., PS-NEURO ex 56 to B.M.), Italian Ministry of Research and University (MIUR, to B.M.), and the OASI (IRCCS) Institution for Research and Care on Mental Retardation and Brain Aging Troina (EN) Italy.
- Tedroff JM: Functional consequences of dopaminergic degeneration in Parkinson's disease. Adv Neurol. 1999, 80: 67-70.PubMedGoogle Scholar
- Rascol O, Payoux P, Ory F, Ferriera JJ, Brefel-Courbon C, Montastruc JL: Limitations of current Parkinson's disease therapy. Ann Neurol. 2003, 53 (Suppl 3): S3-12. 10.1002/ana.10513.PubMedGoogle Scholar
- Warner TT, Schapira AHV: Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol. 2003, 53: S16-S25. 10.1002/ana.10487.PubMedGoogle Scholar
- Hindle JV: Ageing, neurodegeneration and Parkinson's disease. Age Ageing. 2010, 39: 156-161. 10.1093/ageing/afp223.PubMedGoogle Scholar
- McGeer P, McGeer E: Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord. 2004, 10: S3-7. 10.1016/j.parkreldis.2004.01.005.PubMedGoogle Scholar
- Chen H, Zhang SM, Herman MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE: Non steroidal anti-inflammatory drugs and the risk of Parkinson's disease. Arch Neurol. 2003, 60: 1059-64. 10.1001/archneur.60.8.1059.PubMedGoogle Scholar
- Chen H, Jacobs EJ, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A: Nonsteroidal antiinflammatory drug use and the risk forParkinson's disease. Ann of Neurol. 2005, 58: 963-967. 10.1002/ana.20682.Google Scholar
- Morale MC, Serra PA, Delogu MR, Migheli R, Rocchitta G, Tirolo C, Caniglia S, Testa N, L'Episcopo F, Gennuso F, Scoto GM, Barden N, Miele E, Desole MS, Marchetti B: Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide. The FASEB Journal. 2004, 18: 164-166.PubMedGoogle Scholar
- Marchetti B, Kettenmann H, Streit WJ: Glia-Neuron Crosstalk in Neuroinflammation, Neurodegeneration and Neuroprotection. Brain Res Review Special Issue. 2005, 482: 129-489.Google Scholar
- Marchetti B, Serra PA, L'Episcopo F, Tirolo C, Caniglia S, Testa N, Cioni S, Gennuso F, Rocchitta G, Desole MS, Mazzarino MC, Miele E, Morale MC: Hormones are key actors in gene × environment interactions programming the vulnerability to Parkinson's disease: Glia as a common final pathway. Ann NY Acad Sci. 2005, 1057: 296-318. 10.1196/annals.1356.023.PubMedGoogle Scholar
- Marchetti B, Serra PA, Tirolo C, L'Episcopo F, Caniglia S, Gennuso F, Testa N, Miele E, Desole MS, Barden N, Morale MC: Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental Parkinsonism: pivotal role for glia-neuron interactions. Brain Res Reviews. 2005, 48: 302-321. 10.1016/j.brainresrev.2004.12.030.Google Scholar
- Morale MC, L'Episcopo F, Tirolo C, Giaquinta G, Caniglia S, Testa N, Arcieri P, Serra PA, Lupo G, Alberghina M, Harada N, Honda S, Panzica GC, Marchetti B: Loss of Aromatase Cytochrome P450 function as a risk factor for Parkinson's disease?. Brain Res Rev. 2008, 57: 431-443. 10.1016/j.brainresrev.2007.10.011.PubMedGoogle Scholar
- Hirsch EC, Hunot S: Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8: 382-397. 10.1016/S1474-4422(09)70062-6.PubMedGoogle Scholar
- Gao HM, Hong JS: Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008, 29: 357-65. 10.1016/j.it.2008.05.002.PubMedGoogle Scholar
- Przedborski S: Inflammation and Parkinson's disease pathogenesis. Mov disord. 2010, 25 (Suppl 1): S55-7. 10.1002/mds.22638.PubMedGoogle Scholar
- Hoang T, Choi DK, Nagai M, Wu DC, Nagata T, Prou D, Wilson GL, Vila M, Jackson-Lewis V, Dawson V, Dawson TM, Chesselet MF, Przedborski S: Neuronal NOS and ciyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson's Disease. Free Radical Biology & Medicine. 2009, 47: 1049-1056.Google Scholar
- Boger HA, Granholm AC, McGinty JF, Middaugh LD: A dual-hit animal model for age-related parkinsonism. Prog in Neurobiol. 2010, 90: 217-229. 10.1016/j.pneurobio.2009.10.013.Google Scholar
- L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B: Glia as a turning point in the therapeutic strategy in Parkinson's disease. CNS Neurol Disord Drug Targets. 2010, 9: 349-72.PubMedGoogle Scholar
- McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988, 38: 1285-91.PubMedGoogle Scholar
- Langston JW, Forno LS, Tetrud J, Reevers AG, Kaplan JA, Karluk D: Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol. 1999, 46: 598-605. 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F.PubMedGoogle Scholar
- Kurkowska-Jastrzebska I, Wrońska A, Kohutnicka M, Członkowski A, Członkowska A: The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol. 1999, 156: 50-61. 10.1006/exnr.1998.6993.PubMedGoogle Scholar
- Gao HM, Liu B, Zhang W, Hong JS: Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci. 2004, 24: 395-401. 10.1016/S0165-6147(03)00176-7.Google Scholar
- McGeer P, McGeer EG: Glial reactions in Parkinson's disease. Mov Disord. 2008, 23: 474-83. 10.1002/mds.21751.PubMedGoogle Scholar
- Marchetti B, Abbracchio MP: To be or not to be (inflamed) is that the question in anti-inflammatory drug therapy of neurodegenerative diseases?. Trends in Pharmacological Sci. 2005, 26: 517-525. 10.1016/j.tips.2005.08.007.Google Scholar
- Whitton PS: Inflammation as a causative factor in the aetiology of Parkinson's disease. Brit J Pharmacol. 2007, 150: 963-976. 10.1038/sj.bjp.0707167.Google Scholar
- Tansey MG, Goldberg MS: Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010, 37: 510-8. 10.1016/j.nbd.2009.11.004.PubMed CentralPubMedGoogle Scholar
- Liberatore GT, Jacksons-Lewis V, Vukosavic C, Mandir AS, Vila M, McAuliffe WG: Inducibile nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat Med. 1999, 5: 1403-1409. 10.1038/70978.PubMedGoogle Scholar
- Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C: Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci. 2002, 22: 1763-71.PubMedGoogle Scholar
- Zhang W, Wang T, Pei Z, Miller DS, Wu X, Blocl ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J: Aggragated alpha synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005, 19: 533-542. 10.1096/fj.04-2751com.PubMedGoogle Scholar
- Zhang W, Dallas S, Zhang D, Guo JP, Pang H, Wilson B: Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant Alpha-Synuclein. Glia. 2007, 55: 1178-1188. 10.1002/glia.20532.PubMedGoogle Scholar
- Purisai MG, McCormack AL, Cumine S, Li J, Isla MZ, Di Monte D: Microglial activation is a priming event leading tom paraquat-induced dopaminergic cell degeneration. Neurobiol Dis. 2007, 25: 392-400. 10.1016/j.nbd.2006.10.008.PubMed CentralPubMedGoogle Scholar
- Hu X, Zhang D, Pang H, Caudle WM, Li Y, Gao H: Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol. 2008, 181: 7194-7204.PubMed CentralPubMedGoogle Scholar
- Mander P, Brown G: Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual key mechanism of inflammatory degeneration. J Neuroinflammation. 2005, 2: 20-27. 10.1186/1742-2094-2-20.PubMed CentralPubMedGoogle Scholar
- Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB: Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem. 2000, 74: 2213-6. 10.1046/j.1471-4159.2000.0742213.x.PubMedGoogle Scholar
- Iravani MM, Kashefi K, Mander P, Rose S, Jenner P: Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience. 2002, 110: 49-58. 10.1016/S0306-4522(01)00562-0.PubMedGoogle Scholar
- Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales K, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM: Minocycline prevents nigrostriatal dopaminergic neurodegeneration in MPTP model of Parkinson's disease. Proc Natl Acad Sci. 2001, 98: 14669-14674. 10.1073/pnas.251341998.PubMed CentralPubMedGoogle Scholar
- Teismann P, Ferger B: Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse. 2001, 39: 167-74. 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U.PubMedGoogle Scholar
- Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S: Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci. 2003, 100: 5473-5478. 10.1073/pnas.0837397100.PubMed CentralPubMedGoogle Scholar
- Kurkowska-Jastrzebska I, Babiuch M, Joniec I, Przybyłkowski A, Członkowski A, Członkowska A: Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int Immunopharmacol. 2002, 2: 1213-8. 10.1016/S1567-5769(02)00078-4.PubMedGoogle Scholar
- Kurkowska-Jastrzebska I, Litwin T, Joniec I, Ciesielska A, Przybyłkowski A, Członkowski A, Członkowska A: Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int Immunopharmacol. 2004, 4: 1307-18. 10.1016/j.intimp.2004.05.006.PubMedGoogle Scholar
- Kurkowska-Jjastrezba I, Członkowski A, Członkowska A: Ibuprofen and the mouse model of Parkinson's disease. Ann Neurol. 2006, 59: 988-9. 10.1002/ana.20860.Google Scholar
- Vijitruth R, Liu M, Choi DY, Nguyen XB, Hunter RL, Bing G: Ciclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model Parkinson's disease. J Neuroinflammation. 2006, 3: 6-10.1186/1742-2094-3-6.PubMed CentralPubMedGoogle Scholar
- Sanchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL, Isacson O: Selective COX2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation. 2004, 1: 6-16. 10.1186/1742-2094-1-6.PubMed CentralPubMedGoogle Scholar
- Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP: Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res. 2003, 966: 245-52. 10.1016/S0006-8993(02)04174-4.PubMedGoogle Scholar
- Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G: Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurology. 2007, 205: 295-312. 10.1016/j.expneurol.2007.02.008.Google Scholar
- Asanuma M, Miyazaki I: Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?. Exp Neurology. 2007, 206: 172-178. 10.1016/j.expneurol.2007.05.006.Google Scholar
- Asanuma M, Miyazaki I: Non-steroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation. Expert Rev Neurotherapeutics. 2006, 6: 1313-1325. 10.1586/14737184.108.40.2063.Google Scholar
- Asanuma M, Miyazaki I, Kohno M, Ogawa N: Neuroprotective effects on non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem. 2001, 76: 1895-1904. 10.1046/j.1471-4159.2001.00205.x.PubMedGoogle Scholar
- Samii A, Etminan M, Wiens MO, Jafari S: NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging. 2009, 26: 769-779. 10.2165/11316780-000000000-00000.PubMedGoogle Scholar
- Gagne JJ, Power MC: Anti-inflammatory drugs and risk of Parkinson's disease: a meta-analysis. Neurology. 2010, 74: 995-1002. 10.1212/WNL.0b013e3181d5a4a3.PubMed CentralPubMedGoogle Scholar
- Klegeris A, McGeer PL: Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res. 2005, 2: 355-65. 10.2174/1567205054367883.PubMedGoogle Scholar
- Klegeris A, McGeer EG, McGeer PL: Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol. 2007, 20: 351-7. 10.1097/WCO.0b013e3280adc943.PubMedGoogle Scholar
- Minghetti L: Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol. 2004, 63: 901-10.PubMedGoogle Scholar
- Patrignani P, Tacconelli S, Sciulli MG, Capone ML: New insights into COX-2 biology and inhibition. Brain Res Brain Res Rev. 2005, 48: 352-9. 10.1016/j.brainresrev.2004.12.024.PubMedGoogle Scholar
- Needleman P, Isakson PC: The discovery and function of COX-2. J Rheumatol Suppl. 1997, 49: 6-8.PubMedGoogle Scholar
- Rao P, Knaus EE: Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008, 11: 81s-110s.PubMedGoogle Scholar
- Wallace B, Reuter C, Cicala W, McKnight MB, Grisham G, Cirino A: Diclofenac derivative without ulcerogenic properties. J Pharmacol. 1994, 257: 249-255.Google Scholar
- Wallace JL, Ignarro LJ, Fiorucci S: Potential cardioprotective actions of NO releasing aspirin. Nat Rev Drug Disc. 2002, 1: 375-382. 10.1038/nrd794.Google Scholar
- Fiorucci S, Antonelli E, Santucci L, Morelli O, Miglietti M, Federici B: Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology. 1999, 116: 1089-1106. 10.1016/S0016-5085(99)70012-0.PubMedGoogle Scholar
- Fiorucci S, Antonelli E: NO-NSAIDs: from inflammatory mediators to clinical readouts. Inflamm Allergy Drug Targets. 2006, 5: 121-131. 10.2174/187152806776383161.PubMedGoogle Scholar
- Fiorucci S, Santucci L, Distrutti E: NSAIDs, coxibs, CINOD and H2S-releasingNSAIDs: what lies beyond the horizon. Digest and Liv Dis. 2007, 39: 1043-1051. 10.1016/j.dld.2007.09.001.Google Scholar
- Ajmone-Cat MA, Nicolini A, Minghetti L: Differential effects of the nonsteroidal antiinflammatory drug flurbiprofen and nitric oxide-releasing derivative, nitroflurbiprofen, on prostaglandin E(2), interleukin-1beta, and nitric oxide synthesis by activated microglia. J Neurosci Res. 2001, 66: 715-722. 10.1002/jnr.10038.PubMedGoogle Scholar
- Bernardo A, Ajmone-Cat MA, Gasparini L, Ongini E, Minghetti L: Nuclear receptor peroxisome proliferator-activated receptor-gamma is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen. J Neurochem. 2005, 92: 895-903. 10.1111/j.1471-4159.2004.02932.x.PubMedGoogle Scholar
- Idris Al, Ralston SH, van't Hof RJ: The nitrosylated flurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action. Eur J Pharmacol. 2009, 602: 215-222. 10.1016/j.ejphar.2008.11.023.PubMedGoogle Scholar
- Keeble JE, Moore PK: Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol. 2002, 137: 295-340. 10.1038/sj.bjp.0704876.PubMed CentralPubMedGoogle Scholar
- Furlan R, Kurne A, Bergami A, Brambilla E, Maucci R, Gasparini L, Butti E, Comi G, Ongini E, Martino G: A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis. J Neuroimmunol. 2004, 150: 10-9. 10.1016/j.jneuroim.2004.01.004.PubMedGoogle Scholar
- Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S: Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine. Neurodegeneration. 1995, 4: 257-69. 10.1016/1055-8330(95)90015-2.PubMedGoogle Scholar
- Tatton NA, Kish SJ: In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience. 1997, 77: 1037-48. 10.1016/S0306-4522(96)00545-3.PubMedGoogle Scholar
- Jackson-Lewis V, Przedborski S: Protocol for the MPTP model of Parkinson's disease. Nature Protocols. 2007, 2: 141-151. 10.1038/nprot.2006.342.PubMedGoogle Scholar
- Aldini G, Carini M, Orioli M, Maffei Facino R, Wenk GL: Metabolic profile of NO-flurbiprofen (HCT1026) in rat brain and plasma: an LC-MS study. Life Sci. 2002, 71: 1487-1500. 10.1016/S0024-3205(02)01915-X.PubMedGoogle Scholar
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 1951, 193: 265-75.PubMedGoogle Scholar
- Franklin KBJ, Paxinos G: The mouse brain in stereotaxic coordinates. Academic Press Inc. 1997Google Scholar
- Baquet ZC, Williams D, Brody J, Smeyne RJ: A comparison of model-basaed (2D) and design-based (3D) stereological methods for estimating cell number in the subtantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience. 2009, 161: 1082-1090. 10.1016/j.neuroscience.2009.04.031.PubMed CentralPubMedGoogle Scholar
- Abercrombie M: Estimation of nuclear population from microtome sections. Anat Rec. 1946, 94: 239-247. 10.1002/ar.1090940210.PubMedGoogle Scholar
- Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19: 312-8. 10.1016/0166-2236(96)10049-7.PubMedGoogle Scholar
- Gainetdinov RR, Fumagalli F, Joness SR, Caron MG: Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem. 1997, 69: 1322-1325. 10.1046/j.1471-4159.1997.69031322.x.PubMedGoogle Scholar
- Ho A, Blum M: Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. J Neurosci. 1998, 18: 5614-29.PubMedGoogle Scholar
- Date I, Felten DL, Felten SY: Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. Brain Res. 1990, 519: 266-76. 10.1016/0006-8993(90)90088-S.PubMedGoogle Scholar
- Sedelis M, Schwarting RKW, Husto JP: Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res. 2001, 125: 109-122. 10.1016/S0166-4328(01)00309-6.PubMedGoogle Scholar
- Alvarez-Fisher D, Henze C, Strenzke C, Westrich J, Ferger B, Holinger GU, Oertel WH, Hartmann A: Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice. Exp Neurol. 2007, 210: 182-193. 10.1016/j.expneurol.2007.10.012.Google Scholar
- Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ: Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain. 2008, 131: 1880-94. 10.1093/brain/awn101.PubMedGoogle Scholar
- Hunter RL, Cheng B, Choi DY, Liu M, Liu S, Cass WA: Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res. 2009, 87: 1913-1921. 10.1002/jnr.22012.PubMed CentralPubMedGoogle Scholar
- Pierre SR, Lemmens MAM, Figueiredo-Pereira ME: Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice. J of Neuroinflammation. 2009, 6: 18-10.1186/1742-2094-6-18.Google Scholar
- Moncada S: Nitric oxide in the vasculature: physiology and pathophysiology. Ann N Y Acad Sci. 1997, 811: 60-67. 10.1111/j.1749-6632.1997.tb51989.x.PubMedGoogle Scholar
- Ritter JM, Harding I, Warren JB: Precaution, cyclooxygenase inhibition and cardiovascular risk. Trends in Pharmacol Sci. 2009, 30: 503-508. 10.1016/j.tips.2009.07.007.Google Scholar
- Prosperi C, Scali C, Pepeu G, Casamenti F: NO-flurbiprofen attenuates excitotoxin-induced brain inflammation, and releases nitric oxide in the brain. Jpn J Pharmacol. 2001, 86: 230-5. 10.1254/jjp.86.230.PubMedGoogle Scholar
- Abdul-Hay SO, Luo J, Ashghodom RT, Thatcher GRJ: NO-flurbiprofen reduces amyloid β, is neuroprotective in cell culture, and anhances cognition in responce to cholinergic blockade. J Neurochem. 2009, 111: 766-776. 10.1111/j.1471-4159.2009.06353.x.PubMed CentralPubMedGoogle Scholar
- Bezard E, Jaber M, Gonon F, Boireau A, Bloch B, Gross CE: Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur J Neurosci. 2000, 8: 2892-900. 10.1046/j.1460-9568.2000.00180.x.Google Scholar
- Collier TJ, Lipton J, Dalkey BF, Palfi S, Chu Y, Sortwell C, Bakai RAE, Sladek JR, Kordower JJH: Aging related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis. 2007, 26: 56-65. 10.1016/j.nbd.2006.11.013.PubMed CentralPubMedGoogle Scholar
- Przybylkowski A, Przybylkowski A, Kurkowska-Jastrzebska I: Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse. Brain Res. 2004, 1019: 144-151. 10.1016/j.brainres.2004.05.095.PubMedGoogle Scholar
- Kaanan NM, Kordower JH, Collier TJ: Age-related changes in dopamine transporters and accumulation of 3-nitrotyrosine in rhesus monkey midbrain dopamine neurons: relevance in selective neuronal vulnerability to degeneration. Eur J Neurosci. 2008, 27: 3205-3215. 10.1111/j.1460-9568.2008.06307.x.Google Scholar
- Gasparini L, Ongini E, Wilcock D, Morgan D: Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res Brain Res Rev. 2005, 48: 400-8. 10.1016/j.brainresrev.2004.12.029.PubMedGoogle Scholar
- Brunelli S, Sciorati C, D'Antona G, Innocenzi A, Covarello D, Perrotta C, Monopoli A, Sanvito F, Bottinelli R, Ongini E, Cossu G, Clementi E: Nitric oxide release combined with non-steroisal anti-inflammatory activity prevents muscular distrophy pathology and enhances stem cell therapy. Proc Natl Acad Sci. 2007, 104: 264-269. 10.1073/pnas.0608277104.PubMed CentralPubMedGoogle Scholar
- Clancy R, Varenika B, Huang W, Ballou L, Attur M, Amin AR, Abramson SB: Nitric oxide synthase/COX cross-talk: nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production. J Immunol. 2000, 165: 1582-7.PubMedGoogle Scholar
- Colasanti M, Suzuki K: The dual personality of NO. Trends Pharmacol Sci. 2000, 21: 249-252. 10.1016/S0165-6147(00)01499-1.PubMedGoogle Scholar
- Guastadisegni C, Minghetti L, Nicolini A, Polazzi E, Ade P, Balduzzi M, Levi G: Prostaglandin E2 synthesis is differentially affected by reactive nitrogen intermediates in cultured rat microglia and RAW 264.7 cells. FEBS Lett. 1997, 413: 314-8. 10.1016/S0014-5793(97)00925-3.PubMedGoogle Scholar
- Guastadisegni C, Nicolini A, Balduzzi M, Ajmone-Cat MA, Minghetti L: Modulation of PGE(2) and TNFalpha by nitric oxide and LPS-activated RAW 264.7 cells. Cytokine. 2002, 19: 175-80. 10.1006/cyto.2002.1955.PubMedGoogle Scholar
- Rocchitta G, Migheli R, Mura MP, Grella G, Esposito G, Marchetti B, Miele E, Desole MS, Miele M, Serra P-A: Signaling pathways in the nitric oxide and iron-induced dopamine release in the striatum of freely mooving rats: role of extracellular Ca2+ and L-type Ca2+ channels. Brain Res. 2005, 1047: 18-29. 10.1016/j.brainres.2005.04.008.PubMedGoogle Scholar
- Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, Volpe BT, Joh TH: Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res. 2003, 964: 288-94. 10.1016/S0006-8993(02)04085-4.PubMedGoogle Scholar
- Sawada H, Hishida R, Hirata Y, Ono K, Suzuki H, Muramatsu S, Nakano I, Nagatsu T, Sawada M: Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine. J Neurosci Res. 2007, 85: 1752-1761. 10.1002/jnr.21241.PubMedGoogle Scholar
- Streit WJ, Mrak RE, Griffin WS: Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation. 2004, 1: 14-10.1186/1742-2094-1-14.PubMed CentralPubMedGoogle Scholar
- Lucin KM, Wyss-Coray T: Immune activation in brain aging and neurodegeneration: too much or too little?. Neuron. 2009, 64: 110-122. 10.1016/j.neuron.2009.08.039.PubMed CentralPubMedGoogle Scholar
- Sandhu JK, Gardaneh M, Iwasiow R, Lanthier P, Gangaraju S, Ribecco-Lutkiewicz M: Astrocyte-secreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity. Neurobiology of Disease. 2009, 33: 405-414. 10.1016/j.nbd.2008.11.016.PubMedGoogle Scholar
- Smeyne M, Goloubeva O, Smeyne RJ: Strain-dependent susceptibility to MPTP and MPTP(+)-induced parkinsonism is determined by glia. Glia. 2001, 34: 73-80. 10.1002/glia.1042.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.